# Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

Study · id `cardio:ct-nct04981041` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04981041](<https://clinicaltrials.gov/study/NCT04981041>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04981041

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 602 participants.

## Technical summary

Registry record NCT04981041. Randomized; single masking; primary purpose treatment. Start 2021-12-16 (actual); primary completion 2026-05-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 602 participants (enrolled count; ClinicalTrials.gov record NCT04981041, source copy `cardio:ctgov-nct04981041-2026-06-02`, retrieved 2026-11-18)
- Started: 2021-12-16 (actual) (ClinicalTrials.gov record NCT04981041, source copy `cardio:ctgov-nct04981041-2026-06-02`, retrieved 2026-11-18)
- Primary completion: 2026-05-22 (actual) (ClinicalTrials.gov record NCT04981041, source copy `cardio:ctgov-nct04981041-2026-06-02`, retrieved 2026-11-18)
- Completion: 2026-05-30 (actual) (ClinicalTrials.gov record NCT04981041, source copy `cardio:ctgov-nct04981041-2026-06-02`, retrieved 2026-11-18)
- Countries: Austria; Germany (ClinicalTrials.gov record NCT04981041, source copy `cardio:ctgov-nct04981041-2026-06-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04981041-2026-06-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
- Acronym: EPIDAURUS
- Condition: Acute Coronary Syndrome
- Condition: Atrial Fibrillation
- Intervention (Drug): Prasugrel or Ticagrelor
- Intervention (Drug): Clopidogrel
- Lead sponsor: Ludwig-Maximilians - University of Munich
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Ludwig-Maximilians - University of Munich (`cardio:org-ludwig-maximilians-university-of-munich`)

## Provenance

Content hash: 9285000bf7dffabc0172edbc07259656f3fcbf5d41baa2a5f86d01835f31e69c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
